Accessibility Menu
Resonance Health logo

Resonance Health(ASX) RHT

Market CapA$25.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1994)-100%
5 Year-61%
1 Year+29%
1 Month+6%
A$0.05
+0.00%
+0.00Today
Resonance Health last closing stock price
MetricPriceDate
Last closeAUD 0.052026-08-14
Resonance Health stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.67%AUD 0.062026-08-07
1 month+6%AUD 0.052026-07-15
3 month+23.26%AUD 0.042026-05-14
Year to date+8.16%AUD 0.052025-12-31
1 year+29.27%AUD 0.042025-08-14
3 year-18.46%AUD 0.072023-08-15
5 year-60.74%AUD 0.142021-08-13
Since inception-99.62%AUD 14.091994-04-25

Resonance Health Financials at a Glance

Market Cap

A$25.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$24.37M

Net Income (TTM)

A$460.16K

EPS (TTM)

A$0.00

P/E Ratio

33.12

Dividend

A$0.00

Beta (Volatility)

0.04 (Low)

Price

A$0.05

Volume

19,700

Open

A$0.05

Previous Close

A$0.05

Daily Range

A$0.05 - A$0.05

52-Week Range

A$0.03 - A$0.06

Estimated Earnings Date

Feb 26, 2026

RHT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Resonance Health

Resonance Health Limited is a global provider of healthcare technology and services, specializing in software-as-medical devices. The company focuses on non-invasive, MRI-based diagnostic tools and serves markets across multiple regions, including Asia Pacific, Americas, Europe, Middle East, and Africa.

Products and Services
  • FerriScan for quantifying liver iron concentration
  • HepaFat-AI for real-time liver fat quantification
  • Contract Research Organization (CRO) services for clinical trials
Growth Outlook
  • Recent quarterly revenue reached AUD 7.98 million, a significant increase
  • Strong demand for AI-driven diagnostic tools is expected to drive growth
  • Expansion into new markets enhances potential for revenue growth
Financial Highlights
  • Net income for the latest quarter was AUD 1.47 million, indicating profitability
  • Gross profit margin stands at 94%, showcasing operational efficiency
  • Current ratio of 1.87 suggests strong liquidity position
Resonance Health Limited has established itself as a leader in the healthcare technology sector, particularly in MRI-based diagnostics. The company's innovative products, such as FerriScan and HepaFat-AI, leverage advanced technology to provide critical insights into liver health, which is increasingly important in managing chronic diseases. The recent financial performance indicates a positive trajectory, with substantial revenue growth and a strong gross profit margin. The company's focus on expanding its market presence and enhancing its product offerings positions it well for future growth. Investors may find Resonance Health Limited an intriguing opportunity within the healthcare technology landscape.
AI Generated • Jul 24, 2026

Industry

Healthcare Equipment and Supplies

CEO

Andrew Duncan Harrison

Headquarters

Burswood, WA 6100, AU

RHT Financials

Key Financial Metrics (TTM)

Gross Margin

96.54%

Operating Margin

14.03%

Net Income Margin

5.56%

Return on Equity

7.57%

Return on Capital

-14.62%

Return on Assets

4.28%

Earnings Yield

3.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$25.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

477.12M

Volume

19.70K

Avg. Volume

256.49K

Financials (TTM)

Gross Profit

A$23.89M

Operating Income

A$2.12M

EBITDA

A$422.91K

Operating Cash Flow

A$2.95M

Capital Expenditure

-A$498.57K

Free Cash Flow

A$2.45M

Cash & ST Invst.

A$2.69M

Total Debt

A$5.20M

Resonance Health Performance Analysis

Resonance Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 3,827,976N/A
20232023-06-30AUD 4,404,36015.1%
20242024-06-30AUD 8,589,49095.0%
20252025-06-30AUD 11,073,01828.9%
Resonance Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3063.0%
Q22024-12-31-2.1%
Q42025-06-3012.5%
Q22025-12-3136.0%
Resonance Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.00N/A
20232023-06-30AUD -0.00-32.0%
20242024-06-30AUD 0.00N/A
20252025-06-30AUD -0.00N/A
Resonance Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30233.3%
Q22024-12-31-243.7%
Q42025-06-3034.8%
Q22025-12-31300.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$7.98M

+144.2%

Gross Profit

A$7.50M

+129.5%

Gross Margin

94.00%

N/A

Market Cap

A$25.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.40M

N/A

Employees

18

N/A

Net Income

A$1.47M

+362.7%

EBITDA

A$1.58M

+603.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$2.69M

-54.4%

Total Debt

A$5.20M

+1520.0%

Accounts Receivable

A$3.54M

+180.2%

Inventory

A$0.00

N/A

Long Term Debt

A$4.67M

+2311.4%

Short Term Debt

A$527.86K

+107.5%

Return on Assets

4.28%

N/A

Return on Invested Capital

13.42%

N/A

Free Cash Flow

A$136.90K

+132.9%

Operating Cash Flow

A$173.36K

+220.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IDT.AXIDT Australia Limited
A$0.04-6.38%
IME.AXImExHS Limited
A$0.31-3.13%
AT1.AXAtomo Diagnostics Limited
A$0.02-5.56%
NTI.AXNeurotech International Limited
A$0.01+7.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About RHT

What is the current price of Resonance Health?

Resonance Health is trading at A$0.05 per share.

What is the 52-week range for Resonance Health?

Over the past 52 weeks, Resonance Health has traded between A$0.03 and A$0.06.

How much debt does Resonance Health have?

As of the most recent reporting period, Resonance Health reported total debt of A$3.80M.

How much cash does Resonance Health have on hand?

Resonance Health reported A$2.98M in cash and cash equivalents in its most recent financial results.

What is Resonance Health’s dividend yield?

Resonance Health does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.